Clinical Trials Logo

Metastatic Solid Malignancies clinical trials

View clinical trials related to Metastatic Solid Malignancies.

Filter by:
  • None
  • Page 1

NCT ID: NCT04850755 Recruiting - Clinical trials for Metastatic Solid Malignancies

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Start date: March 8, 2021
Phase: Phase 1
Study type: Interventional

This is a single-centre, phase 1a (dose escalation) and 1b (dose expansion) study to evaluate the safety and tolerability of oral Selinexor in combination with nivolumab and ipilimumab in patients with advanced solid malignancies.

NCT ID: NCT03107663 Completed - Hodgkin Lymphoma Clinical Trials

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

Start date: June 19, 2017
Phase: Phase 1
Study type: Interventional

To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to determine imaging parameters for optimal lymphoid and tumor visualization.

NCT ID: NCT02705703 Withdrawn - Cancer Clinical Trials

Consolidation Therapy in Patients With Metastatic Solid Malignancies

Start date: July 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the effectiveness of Tumor Associated Peptide Antigens (TAPA) pulsed dendritic cell injections as a potential consolidation therapy for patients with metastatic solid malignancies (SM). The investigators hypothesize that treatment of patients with metastatic SM who demonstrate a tumor response, or whose disease remains stable, after conventional first-line systemic therapy AND who lack an available, potentially curative therapeutic intervention and whose tumor cells and/or blood express at least one (1) TAPA of a defined panel of TAPAs will result in TAPA-specific T-cell responses without significant toxicities. The investigators also hypothesize CD4+ and CD8+ T-cell responses generated against specific TAPAs may translate into clinical antitumor activity.

NCT ID: NCT02439723 Withdrawn - Clinical trials for Metastatic Solid Malignancies

Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients

Start date: March 2016
Phase: Phase 1
Study type: Interventional

The FDA and Health Canada have approved regorafenib at a daily dose of 160mg for the treatment of metastatic colorectal cancer and gastrointestinal stromal cancer; however, the 160 mg dose is not well tolerated by patients, especially women. The purpose of this study is to determine if lean body mass and acidity in the intestinal tract impact how regorafenib is absorbed into the bloodstream and then broken down and removed from the body. This may explain the side effects experienced at the 160 mg dose, especially by women, and inform regorafenib dosing in the future.